LuPSMA and enzalutamide: a promising combination Presented ByProf. Louise Emmet, St Vincent’s Hospital Sydney, Australia TrialPhase 2, ENZA-p ConferenceESMO 2023 19 December, 2023 12:15
No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy Presented ByProf. Arlene Siefker-Radtke, MD Anderson Cancer Centre, USA TrialPhase 3, THOR ConferenceESMO 2023 19 December, 2023 11:20
Combining PARP inhibition and androgen receptor-signalling inhibition improves radiographic progression-free survival in HRR-deficient mCRPC Presented ByProf. Karim Fizazi, Institute Gustave Roussy, France TrialPhase 3, TALAPRO-2 ConferenceASCO 2023 2 August, 2023 09:24
Erdafitinib outperforms chemotherapy in FGFR-altered advanced urothelial cancer Presented ByDr Yohann Loriot, Gustave Roussy Cancer Institute, France TrialPhase 3, THOR ConferenceASCO 2023 2 August, 2023 09:20
Probiotic CBM588 seems to improve clinical effect cabozantinib/nivolumab in mRCC Presented ByDr Hedyeh Ebrahimi, Tehran University of Medical Sciences, Iran TrialPhase 1 ConferenceASCO 2023 2 August, 2023 09:11
Exploratory analysis of IMvigor130 trial finds no OS benefit from atezolizumab in subgroups Presented ByDr Enrico Grande, MD Anderson Cancer Center, Spain TrialPhase 3, IMvigor130 ConferenceASCO 2023 2 August, 2023 09:08
Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer Presented ByDr Philipp Harter, Kliniken Essen-Mitte, Germany TrialPhase 3, DUO-O ConferenceASCO 2023 1 August, 2023 12:44
ASCO 2023 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceASCO 2023 26 June, 2023 03:07
The road to improving doctor-patient interactions in kidney cancer ExpertDena Battle , KCCure - Kidney Cancer Research Alliance, USA 12 June, 2023 10:37
OS benefit for advanced ovarian cancer patients treated with maintenance olaparib Presented ByProf. Isabelle Ray-Coquard, Centre Léon Bérard, France TrialPhase 3, PAOLA-1/ENGOT-ov25 ConferenceESMO 2022 17 November, 2022 00:57
Maintenance tegafur-uracil does not improve survival in locally advanced cervical cancer Presented ByProf. Keiichi Fujiwara, Saitama Medical University, Japan TrialGOTIC-002 LUFT ConferenceESMO 2022 17 November, 2022 00:52
Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy Presented ByProf. Robert Motzer, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 3, CheckMate 914 ConferenceESMO 2022 17 November, 2022 00:46
Triple therapy improves progression-free survival in patients with advanced RCC versus dual therapy Presented ByProf Toni Choueiri, Dana-Farber Cancer Institute, MA, USA TrialPhase 3, COSMIC-313 ConferenceESMO 2022 17 November, 2022 00:41
Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence Presented ByDr Axel Bex, The Royal Free London NHS Foundation Trust, UK TrialPhase 3, IMmotion-010 ConferenceESMO 2022 17 November, 2022 00:28
Overall survival benefit of abiraterone in mHSPC is maintained for 7 years Presented ByProf. Gerhardt Attard, UCL Cancer Institute London, UK TrialPhase 3, STAMPEDE ConferenceESMO 2022 17 November, 2022 00:23
Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer Presented ByProf. Chris Parker, The Royal Marsden Hospital, UK TrialRADICALS-HD ConferenceESMO 2022 17 November, 2022 00:17
Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer Presented ByDr Rahul Aggarwal, University of California San Francisco, CA, USA TrialPhase 3, PRESTO ConferenceESMO 2022 17 November, 2022 00:13
Exploratory treatment options fail in ccRCC Presented ByProf. Thomas Powles, University of London, UK TrialPhase 2, CALYPSO ConferenceASCO 2022 5 August, 2022 14:18
Adjuvant everolimus did not benefit high-risk renal cell carcinoma Presented ByDr Christopher W. Ryan, Oregon Health & Science University, OR, USA TrialPhase 3, EVEREST ConferenceASCO 2022 5 August, 2022 14:14
Cabozantinib fails as first-line maintenance therapy in urothelial cancer Presented ByProf. Robert Jones, University of Glasgow, UK TrialPhase 2, ATLANTIS ConferenceASCO 2022 5 August, 2022 14:11
177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC Presented ByProf. Michael Hofman, Peter McCallum Cancer Centre, Australia TrialPhase 2, TheraP ConferenceASCO 2022 5 August, 2022 14:08
Enzalutamide performs well in metastatic hormone-sensitive prostate cancer Presented ByProf. Ian Davis, Monash University, Australia TrialPhase 3, ENZAMET ConferenceASCO 2022 5 August, 2022 14:04
Does systematic biopsy add value to the detection rate of prostate cancer? Presented ByDr Enrico Checcucci, University of Turin, Italy ConferenceEAU 2022 22 July, 2022 12:42
PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer Presented ByProf. Lih-Ming Wong, University of Melbourne, Australia TrialPhase 3 ConferenceEAU 2022 22 July, 2022 12:41
Prostate cancer treatments reduce quality of life Presented ByMr André Deschamps, Europa Uomo, Belgium TrialEUPROMS 2.0 ConferenceEAU 2022 22 July, 2022 12:39
PROpel: Good results for abiraterone plus olaparib in mCRPC Presented ByProf. Noel Clarke, University of Manchester, UK TrialPhase 3, PROpel ConferenceEAU 2022 22 July, 2022 12:37
Neoadjuvant hormonal therapy promising in high-risk prostate cancer Presented ByProf. Steven Joniau, UZ Leuven, Belgium TrialPhase 2, ARNEO ConferenceEAU 2022 22 July, 2022 12:35
Darolutamide performs well across subgroups in mHSPC Presented ByProf. Bertrand Tombal, Université Catholique de Louvain, Belgium TrialPhase 3, ARASENS ConferenceEAU 2022 22 July, 2022 12:33
Shorter hospital stay with robotic surgery versus open surgery in bladder cancer Presented ByProf. James Catto, University of Sheffield, UK TrialPhase 3, iROC ConferenceEAU 2022 22 July, 2022 12:30
Improved risk stratification for high-risk NMIBC Presented ByMr Florus de Jong, Erasmus University Medical Center, the Netherlands ConferenceEAU 2022 22 July, 2022 12:28
Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma Presented ByProf. Jürgen Gschwend, Technical University Munich, Germany TrialPhase 3, IMvigor010 ConferenceEAU 2022 22 July, 2022 12:26
New prognostication in N3 penile cancer Presented ByDr James Churchill, St George Hospital, Australia ConferenceEAU 2022 22 July, 2022 12:24
KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC Presented ByProf. Thomas Powles, Barts Cancer Institute, UK TrialPhase 3, KEYNOTE-564 ConferenceEAU 2022 22 July, 2022 12:22
Fewer complications with robotic surgery in renal cancer Presented ByProf. Marc-Oliver Grimm, Universitätsklinikum Jena, Germany TrialPhase 3, OpeRa ConferenceEAU 2022 22 July, 2022 12:19
Enzalutamide with active surveillance reduces prostate-cancer progression JournalJAMA Oncology 22 June, 2022 16:04
Support for risk-adapted androgen deprivation plus high-dose radiotherapy in prostate cancer JournalThe Lancet Oncology 22 April, 2022 15:46
Is bone health being overlooked in men on ADT for prostate cancer? JournalJAMA Network Open 8 April, 2022 16:01
First-line treatment with olaparib significantly improves PFS in mCRPC Presented ByDr Fred Saad, Centre Hospitalier de l’Université de Montréal, Canada TrialPhase 3, PROpel ConferenceASCO GU 2022 8 April, 2022 11:25
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC Presented ByDr Kim Chi, University of British Columbia, Canada TrialPhase 3, MAGNITUDE ConferenceASCO GU 2022 8 April, 2022 11:25
Darolutamide improves OS in mHSPC Presented ByDr Matthew Smith, Massachusetts General Hospital Cancer Center, MA, USA TrialPhase 3, ARASENS ConferenceASCO GU 2022 8 April, 2022 11:24
Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide Presented ByDr Axel Merseburger, Universitätsklinikum Schleswig-Holstein, Germany TrialPhase 3, PRESIDE ConferenceASCO GU 2022 8 April, 2022 11:24
Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence Presented ByDr David Schuster, Emory University School of Medicine, GA, USA TrialPhase 3, SPOTLIGHT ConferenceASCO GU 2022 8 April, 2022 11:24
PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel Presented ByProf. Michael Hofman, Peter MacCallum Cancer Centre, Australia TrialPhase 2, TheraP ConferenceASCO GU 2022 8 April, 2022 11:23
Artificial intelligence improves prediction of long-term outcomes Presented ByDr Osama Mohamad, University of California San Francisco, CA, USA ConferenceASCO GU 2022 8 April, 2022 11:22
Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer Presented ByProf. Neil Fleshner, Princess Margaret Cancer Centre, Canada TrialPhase 2, ACDC-RP ConferenceASCO GU 2022 8 April, 2022 11:22
Addition of abiraterone to ADT/docetaxel does not increase bone loss Presented ByDr Guilhem Roubaud, Institut Bergonié, France TrialPhase 3, PEACE-1 ConferenceASCO GU 2022 8 April, 2022 11:21
Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity Presented ByDr Xin Gao, Massachusetts General Hospital, MA, USA TrialPhase 2, ARDENT ConferenceASCO GU 2022 8 April, 2022 11:21
No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma Presented ByDr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 2, BAYOU ConferenceASCO GU 2022 8 April, 2022 11:19
Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma Presented ByDr Simon Crabb, University of Southampton, UK TrialPhase 2, ATLANTIS ConferenceASCO GU 2022 8 April, 2022 11:18
Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC Presented ByDr Sam Chang, Vanderbilt University Medical Center, TN, USA TrialPhase 3, QUILT-3.032 ConferenceASCO GU 2022 8 April, 2022 11:18
Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma Presented ByDr Yohann Loriot, Institut Gustave Roussy, France TrialPhase 3, LEAP-011 ConferenceASCO GU 2022 8 April, 2022 11:18
Maintenance niraparib fails to improve PFS in advanced urothelial cancer Presented ByDr Francesca Vignani, Ordine Mauriziano Hospital, Italy TrialPhase 2, Meet-URO12 ConferenceASCO GU 2022 8 April, 2022 11:17
First-line avelumab shows clinical activity in advanced urothelial carcinoma Presented ByDr Roberto Iacovelli, Catholic University of Rome, Italy TrialPhase 2, ARIES ConferenceASCO GU 2022 8 April, 2022 11:17
Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma Presented ByDr Wesley Yip, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 2 ConferenceASCO GU 2022 8 April, 2022 11:17
Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma Presented ByProf. Marc-Oliver Grimm, University Hospital Jena, Germany TrialPhase 2, TITAN-TCC ConferenceASCO GU 2022 8 April, 2022 11:17
Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer Presented ByDr Petros Grivas, University of Washington, WA, USA TrialPhase 2, TROPHY-U-01 ConferenceASCO GU 2022 8 April, 2022 11:16
Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin Presented ByProf. Daniel Petrylak, Yale School of Medicine, CT, USA TrialPhase 1/2, EV-103 ConferenceASCO GU 2022 8 April, 2022 11:16
High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib Presented ByDr Axel Bex, Netherlands Cancer Institute, the Netherlands TrialPhase 2, NeoAvAx ConferenceASCO GU 2022 8 April, 2022 11:14
DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up Presented ByDr Toni Choueiri, Dana-Farber Cancer Institute, MA, USA TrialPhase 3, KEYNOTE-564 ConferenceASCO GU 2022 8 April, 2022 11:14
Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC Presented ByDr Marc-Oliver Grimm, University Hospital Jena, Germany TrialPhase 2, TITAN-RCC ConferenceASCO GU 2022 8 April, 2022 11:13
Combined nivolumab/axitinib treatment elicits good response in metastatic RCC Presented ByDr Matthew Zibelman, Fox Chase Cancer Center, PA, USA TrialPhase 1/2 ConferenceASCO GU 2022 8 April, 2022 11:13
Folliculin mutations not associated with sporadic chromophobe RCC Presented ByDr Joseph Jacob, Upstate University Hospital, NY, USA ConferenceASCO GU 2022 8 April, 2022 11:13
Differential patterns of molecular alterations among sites of metastasis in RCC Presented ByDr Rana McKay, University of California San Diego, CA, USA ConferenceASCO GU 2022 8 April, 2022 11:12
Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC Presented ByDr Michael Atkins, Georgetown Lombardi Comprehensive Cancer Center, DC, USA TrialPhase 2, HCRN GU16-260 ConferenceASCO GU 2022 8 April, 2022 11:12
HPV-positive and HPV-negative penile squamous cell carcinoma are molecularly distinct tumours Presented ByDr Bassel Nazha, Emory University, GA, USA ConferenceASCO GU 2022 8 April, 2022 11:11
Atezolizumab does not improve survival in advanced penile cancer Presented ByDr Hielke-Martijn de Vries, Netherlands Cancer Institute, the Netherlands TrialPhase 2, PERICLES ConferenceASCO GU 2022 8 April, 2022 11:11
Biomarkers to distinguish necrosis from teratoma before pcRPLND in testicular cancer Presented ByDr Tim Nestler, University of Cologne, Germany ConferenceASCO GU 2022 8 April, 2022 11:10
No survival benefit found in routine screening MRI for spinal cord compression in prostate cancer JournalThe Lancet Oncology 7 April, 2022 16:18
Immune system-generated antibodies combat ovarian tumors in a lab study JournalCell 4 April, 2022 23:18
Changes in genitourinary cancer management during the pandemic: findings and implications ExpertDr Chris Labaki, Dana-Farber Cancer Institute, MA, USA ConferenceASCO GU 2022 4 April, 2022 00:22
Large phase 3 trial tests novel combinations for metastatic RCC ExpertProf. Toni Choueiri, Dana-Farber Cancer Institute, Harvard Medical School, MA, USA TrialKEYNOTE-581/CLEAR ConferenceASCO GU 2022 4 April, 2022 00:10
Positive phase-3 data for PARP inhibitor niraparib in ovarian cancer ConferenceSociety of Gynecologic Oncology (SGO) Annual Meeting 25 March, 2022 16:47
New ultrasound approach simplifies ovarian cancer detection in average-risk women JournalRadiology 24 March, 2022 15:58
Can nitrogen-based bisphosphonates protect against ovarian cancer? JournalJournal of the National Cancer Institute 18 March, 2022 16:40
ASCO GU 2022 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceASCO GU 2022 14 March, 2022 07:21
Breast, cervical screening suboptimal in transgender individuals JournalAmerican Journal of Clinical Oncology 10 March, 2022 23:32
Many cancer centers not following prostate-screening recommendations JournalJAMA Internal Medicine 9 March, 2022 15:49
Bayer’s Nubeqa drug significantly prolongs survival in prostate cancer trial JournalThe New England Journal of Medicine 17 February, 2022 23:09
Removing fallopian tubes during hysterectomy may curb ovarian cancer risk JournalJAMA Network Open 17 February, 2022 23:06
Online tool helps ovarian-cancer patients manage symptoms JournalJournal of Clinical Oncology 11 February, 2022 15:58
Cemiplimab boosts survival in recurrent cervical cancer JournalThe New England Journal of Medicine 9 February, 2022 23:00
Pregnancy outcomes improving after treatment for high-grade cervical neoplasia JournalAnnals of Internal Medicine 7 February, 2022 23:00
Brachytherapy boost may allow for shorter androgen deprivation therapy with EBRT JournalJAMA Oncology 1 February, 2022 00:01
BRCA1/2 pathogenic variants linked to prostate, pancreatic and stomach cancers JournalJournal of Clinical Oncology 31 January, 2022 15:55
AI can identify, grade prostate cancer like a pathologist JournalNature Medicine 24 January, 2022 23:12
Abiraterone therapy tied to longer survival in Black vs. white men with metastatic castration-resistant prostate cancer JournalJAMA Network Open 13 January, 2022 16:16
Blacks in clinical trials respond better than whites to radiation for localized prostate cancer JournalJAMA Network Open 11 January, 2022 16:30
Fallopian organoids promising for ovarian cancer prediction in women with BRCA mutations JournalCell Reports 5 January, 2022 22:16
Second-generation antiandrogens linked to higher depression risk JournalJAMA Network Open 31 December, 2021 16:33
Drop in PSA tied to better outcomes of apalutamide therapy in prostate cancer JournalEuropean Urology 30 December, 2021 15:59
Pathogenic TP53 gene mutations linked with aggressive prostate cancer JournalEuropean Urology 27 December, 2021 17:25
Loss, mutation of NCOR2 likely fuels prostate cancer progression, resistance JournalCell Reports 23 December, 2021 01:32
Is recovery of sexual function after radical prostatectomy surgeon dependent? JournalJAMA Surgery 6 December, 2021 17:24
Upfront immunotherapy combo means less time on treatment in advanced kidney cancer JournalClinical Cancer Research 25 November, 2021 17:10
Maintenance olaparib benefits sustained beyond 2 years treatment JournalThe Lancet Oncology 24 November, 2021 19:25
PSA testing rose after revised USPSTF guideline, even among those deemed ineligible JournalJAMA Oncology 19 November, 2021 23:35
Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment TrialPhase 3, PEACE-1, STAMPEDE, ARCHES ConferenceESMO 2021 19 November, 2021 09:27
TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC Presented ByProf. Janet Brown, University of Sheffield, UK TrialPhase 2, STAR ConferenceESMO 2021 19 November, 2021 09:26
Modified ipilimumab schedule reduces risk of grade 3/4 adverse events Presented ByDr Naveen Vasudev, St James University Hospital, UK TrialPhase 2, PRISM ConferenceESMO 2021 19 November, 2021 09:26
Optimal neoadjuvant dose ipilimumab/nivolumab in stage III urothelial cancer Presented ByDr Jeroen van Dorp, Netherlands Cancer Institute, the Netherlands TrialPhase 1, NABUCCO ConferenceESMO 2021 19 November, 2021 09:26
Better survival with neoadjuvant dose-dense MVAC regimen in MIBC Presented ByDr Christian Pfister, Rouen University Hospital, France TrialPhase 3, VESPER ConferenceESMO 2021 19 November, 2021 09:25
PARP inhibitor rechallenge improves PFS in ovarian cancer Presented ByDr Eric Pujade-Lauraine, Université Paris Descartes, France TrialPhase 3, OReO/ENGOT Ov-38 ConferenceESMO 2021 19 November, 2021 09:24
Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer Presented ByProf. Nicoletta Colombo, Istituto Europeo di Oncologia, Italy TrialPhase 3, KEYNOTE-826 ConferenceESMO 2021 19 November, 2021 09:23
Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer Presented ByProf. David O’Malley, Ohio State University, USA TrialPhase 2, KEYNOTE-158 ConferenceESMO 2021 19 November, 2021 09:23
HRR mutational status is prognostic and predictive biomarker olaparib activity Presented ByDr Joyce Liu, Dana-Farber Cancer Institute, MA, USA TrialPhase 3, NRG-GY004 ConferenceESMO 2021 19 November, 2021 09:20
Premenopausal oophorectomy tied to increased risk of cognitive impairment JournalJAMA Network Open 16 November, 2021 22:46
Acute urinary retention tied to increased risk of certain cancers JournalThe BMJ 16 November, 2021 22:32
Older HPV vaccine cuts cervical cancer rate up to 87%, study finds JournalThe Lancet 4 November, 2021 14:32
Cancer patients treated with PARP inhibitors need monitoring for pancytopenia JournalJAMA Oncology 2 November, 2021 17:01
Genetic test can help pinpoint best treatment for men with high-risk prostate cancer ConferenceAmerican Society for Radiation Oncology (ASTRO) Annual Meeting 1 November, 2021 20:08
Shortened course of radiotherapy the new standard following prostatectomy ConferenceAmerican Society for Radiation Oncology (ASTRO) Annual Meeting 28 October, 2021 15:24
Androgen-annihilation therapy prolongs progression-free survival in metastatic prostate cancer JournalThe Lancet Oncology 22 October, 2021 18:05
No decline in health-related quality of life after radical cystectomy JournalEuropean Urology 21 October, 2021 18:03
Online risk tool facilitates decision making in early, non-metastatic prostate cancer JournalEuropean Urology 8 October, 2021 23:01
Benign ovarian cysts a common side effect of mTor-inhibitor therapy JournalBMJ Open 1 October, 2021 21:59
New standard of care for metastatic and non-metastatic prostate cancer ConferenceESMO 2021 Congress 24 September, 2021 16:41
PSMA PET imaging pinpoints most pelvic nodal metastases in high-risk prostate cancer JournalJAMA Oncology 21 September, 2021 23:16
Pembrolizumab hikes survival by 36% at 24-month mark in cervical cancer study JournalThe New England Journal of Medicine 20 September, 2021 17:25
Adding ADT to radiation works better than upping radiation dose for some prostate cancers JournalProstate Cancer and Prostatic Diseases 16 September, 2021 16:18
Support for gene-specific risk-reduction strategies in Lynch syndrome JournalJAMA Network Open 13 September, 2021 15:45
Best of EAU: Highlights on bladder cancer Presented ByProf. Morgan Rouprêt, Pitié-Salpêtrière Hospital, Paris, France ConferenceEAU 2021 31 August, 2021 12:26
ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer Presented ByProf. Jürgen Gschwend, Technical University Munich, Germany TrialPhase 3, IMvigor010, IMvigor011 ConferenceEAU 2021 31 August, 2021 12:26
Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma Presented ByProf. Thomas Powles, Barts Cancer Centre, London, UK TrialPhase 3, DANUBE ConferenceEAU 2021 31 August, 2021 12:26
Circulating tumour cells could aid in the decision to give neoadjuvant chemotherapy Presented ByDr Nick Beije, Erasmus Medical Center, Rotterdam, the Netherlands TrialCirGuidance 31 August, 2021 12:26
Best of EAU: New advances in testicular and penile cancer Presented ByProf. Maarten Albersen, UZ Leuven, Belgium ConferenceEAU 2021 31 August, 2021 12:23
Recommendations for the management of indeterminate small testis masses Presented ByMr Shafi Wardak, University College London Hospitals, UK ConferenceEAU 2021 31 August, 2021 12:23
Residual tumour resection in case of elevated markers Presented ByDr Yue Che, University of Düsseldorf, Germany ConferenceEAU 2021 31 August, 2021 12:23
Best of EAU: Updates on imaging and treatment of prostate cancer Presented ByProf. Alberto Briganti, IRCCS Ospedale San Raffaele, Milan, Italy TrialSTHLM3MRI, TITAN ConferenceEAU 2021 31 August, 2021 12:15
Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC Presented ByProf. Karim Fizazi, University of Paris-Saclay, Villejuif, France TrialPhase 3, PEACE-1 ConferenceEAU 2021 31 August, 2021 12:15
177Lu-PSMA-617: A new class of effective therapy Presented ByProf. Johann de Bono; Prof. Michael Hofman TrialVISION, TheraP ConferenceEAU 2021 31 August, 2021 12:15
In women with breast or ovarian cancer, pathogenic gene variants linked with increased survival JournalJournal of the National Cancer Institute 27 August, 2021 15:48
Novel blood test plus MRI-targeted biopsy shows promise for prostate-cancer screening JournalThe Lancet Oncology 20 August, 2021 16:28
Adjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer Presented ByProf. Linda Mileshkin, Peter MacCallum Cancer Center, Australia TrialPhase 3, OUTBACK ConferenceASCO 2021 12 August, 2021 23:24
VISION trial shows improved survival with 177Lu-PSMA-617 in mCRPC Presented ByDr Michael Morris, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 3, VISION ConferenceASCO 2021 12 August, 2021 23:18
Novel drug combination for recurrent ovarian cancer Presented ByProf. David O’Malley, Ohio State University, OH, USA TrialPhase 1/2, FORWARD II ConferenceASCO 2021 12 August, 2021 22:43
Abiraterone added to ADT + docetaxel nearly doubles survival in de novo mCSPC Presented ByDr Karim Fizazi , Institut Gustav Roussy, France TrialPhase 3, PEACE-1 ConferenceASCO 2021 12 August, 2021 22:19
Dual HER2-blockade shows anti-tumour activity in patients with uterine cancer Presented ByDr Eugene Ahn, Cancer Treatment Centers of America, IL, USA TrialPhase 2, TAPUR ConferenceASCO 2021 12 August, 2021 21:45
Promising efficacy and safety of feladilimab in recurrent/metastatic urothelial carcinoma Presented ByDr Arjun Balar , Perlmutter Cancer Center, NY, USA TrialPhase 1, INDUCE-1 ConferenceASCO 2021 12 August, 2021 12:30
Cervical cancer screening tied to stable or declining incidence, mortality JournalCancer 9 August, 2021 23:05
The EFFORT needed to overcome PARP resistance in ovarian cancer Presented ByDr. Shannon Neville Westin, University of Texas, MD Anderson Center TrialPhase 2, EFFORT JournalPhysician's Weekly ConferenceASCO 2021 6 August, 2021 12:40
Androgen blockers likely boost survival in older men with non-metastatic CR prostate cancer JournalThe Lancet Oncology 5 August, 2021 23:47
Survival outcomes improving for certain adolescent and young adult cancers JournalCancer 26 July, 2021 23:33
Urinary thromboxane B2 may be marker of aggressive prostate cancer in Black men JournalJournal of the National Cancer Institute 23 July, 2021 17:02
Combination therapy shows promise in oligorecurrent pelvic-node relapses of prostate cancer JournalEuropean Urology 22 July, 2021 22:55
Common advanced prostate cancer treatments not tied to significant cognitive decline JournalJAMA Network Open 20 July, 2021 23:01
Transperineal prostate biopsy safe, effective under local anesthesia JournalUrology 16 July, 2021 22:51
Nicotine by-product in urine a potential biomarker of bladder cancer recurrence ConferenceEuropean Association of Urology Congress 2021 12 July, 2021 18:00
MRI screening for prostate cancer prevents many unnecessary biopsies JournalThe New England Journal of Medicine 9 July, 2021 18:36
Guideline-concordant multimodality care tied to fewer deaths in high-risk prostate cancer JournalJAMA Network Open 8 July, 2021 23:19
Adding pembrolizumab to chemo provides little or no benefit in urothelial cancer JournalThe Lancet Oncology 25 June, 2021 17:07
Adding pembrolizumab to chemo provides little or no benefit in urothelial cancer JournalThe Lancet Oncology 25 June, 2021 17:07
No need to raise salvage radiation dose after prostatectomy JournalEuropean Urology 24 June, 2021 22:00
Biomarkers pinpoint resistant prostate cancer that may benefit from addition of apalutamide JournalJAMA Oncology 16 June, 2021 23:03
Radical prostatectomy shifting to higher-risk cases in era of active surveillance JournalJAMA Network Open 15 June, 2021 15:42
Adjuvant likely bests salvage radiation in high-risk prostate cancer JournalJournal of Clinical Oncology 14 June, 2021 23:58
Genetic analysis shows race-specific tumor alterations tied to racial disparities in prostate cancer JournalCommunications Biology 9 June, 2021 23:28
Targeted radiotherapy improves survival in metastatic castration-resistant prostate cancer ConferenceAmerican Society of Clinical Oncology annual meeting 4 June, 2021 16:39
Pelvic strength helps determine when continence returns after radical prostatectomy JournalUrology 31 May, 2021 16:01
Longer-term analysis finds survival benefit of atezolizumab in metastatic bladder cancer JournalEuropean Urology 24 May, 2021 16:10
Low diagnostic yield with cystoscopy and CT urography for urinary tract cancers JournalJAMA Network Open 11 May, 2021 22:23
Carboplatin monotherapy wanting in vulnerable elderly with ovarian cancer JournalJAMA Oncology 28 April, 2021 16:19
Patients on hormonal therapies for cancer should be monitored for heart risk – AHA JournalCirculation: Genomic and Precision Medicine 26 April, 2021 19:18
Loss of MAP3K7 and CHD1 expression drive recurrence, resistance in prostate cancer JournalMolecular Cancer Research 23 April, 2021 15:32
Biologic drug nearly doubles overall survival in metastatic triple-negative breast cancer JournalThe New England Journal of Medicine 21 April, 2021 23:00
ASCO Genitourinary Cancers Symposium: New therapy prolongs survival for patients with urothelial carcinoma Presented ByDr. Thomas Powles, Barts Cancer Centre, London, UK TrialPhase 3, EV-301 JournalPhysician’s Weekly ConferenceASCO GU 2021 15 April, 2021 16:08
ASCO-GU Highlight: Cabozantinib plus nivolumab provides better QoL than sunitinib Presented ByDr. David Cella , Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, USA TrialPhase 3, CheckMate-9ER JournalPhysician’s Weekly ConferenceASCO GU 2021 13 April, 2021 15:44
Novel genomic alterations in circulating tumor cells tied to castrate-resistant prostate cancer JournalMolecular Cancer Research 9 April, 2021 22:55
BRCA1/2 mutations raise risk for endometrial cancer, too JournalJournal of the National Cancer Institute 1 April, 2021 17:11
Targeting glutamine could curb castration-resistant prostate cancer JournalProceedings of the National Academy of Sciences of the United States of America 29 March, 2021 22:57
Researchers call for an overhaul of licensing and funding of anti-cancer drugs Presented ByDr David O’Reilly, Cork University Hospital, Ireland ConferenceASCO GU 2021 24 March, 2021 15:08
Exploring a new strategy for metastatic germ cell tumours Presented ByMs Shalini Subramaniam, NHMRC Clinical Trials Centre, University of Sydney, Australia TrialPhase 3, P3BEP ConferenceASCO GU 2021 24 March, 2021 15:08
Poorer outcomes in bladder cancer predicted by race/ethnicity and gender Presented ByDr Shaakir Hasan, New York Proton Centre, USA ConferenceASCO GU 2021 24 March, 2021 15:03
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 3 results Presented ByDr Thomas Powles, Barts Cancer Centre, UK TrialPhase 3, EV-301 ConferenceASCO GU 2021 24 March, 2021 15:03
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 2 results Presented ByDr Arjun Vasant Balar, NYU Langone Medical Oncology, USA ConferenceASCO GU 2021 24 March, 2021 15:02
New standard of care recommended for patients with upper tract urothelial cancer Presented ByDr Alison Birtle, Rosemere Cancer Centre, UK TrialPhase 3, POUT ConferenceASCO GU 2021 24 March, 2021 15:02
Signature DNA alterations in subtypes of bladder cancer Presented ByDr Andrew Thomas Lenis, Memorial Sloan Kettering Cancer Centre, New York, USA ConferenceASCO GU 2021 24 March, 2021 15:02
ACE inhibitors associated with superior responses in bladder cancer Presented ByDr Jonathan Thomas, Beth Israel Deaconess Medical Centre, Massachusetts, USA ConferenceASCO GU 2021 24 March, 2021 15:02
Better allocation of research dollars needed Presented ByMs Jeenan Kaiser, University of Alberta, Canada ConferenceASCO GU 2021 24 March, 2021 15:02
Better prediction of favourable responses to immune checkpoint inhibitors in mUC Presented ByDr Marie Alt, Princess Margaret Cancer Centre, Canada ConferenceASCO GU 2021 24 March, 2021 15:02
New prediction model for brain metastasis in germ cell tumours Presented ByDr Ryan Ashkar, Indiana University Simon Comprehensive Cancer Centre, USA ConferenceASCO GU 2021 24 March, 2021 14:58
Reduction in radiation exposure is possible in testicular seminoma surveillance Presented ByProf. Robert Huddart, Royal Marsden Hospital and Institute of Cancer Research, UK TrialPhase 3, TRISST ConferenceASCO GU 2021 24 March, 2021 14:58
New therapeutic option for early metastatic seminoma Principal InvestigatorProf. Siamak Daneshmand, University of Southern California, USA TrialPhase 2, SEMS ConferenceASCO GU 2021 24 March, 2021 14:57
Prognosis of penile cancer associated with HPV status Presented ByDr Adithya Chennamadhavuni, University of Iowa, USA ConferenceASCO GU 2021 24 March, 2021 14:50
Lu177 as a promising new therapy for metastatic prostate cancer Presented ByDr Michael Hofman, Peter MacCallum Cancer Centre, Australia TrialPhase 2, TheraP ConferenceASCO GU 2021 24 March, 2021 14:49
Role of prostate cancer genomics is evolving Presented ByDr Ashley Ross, Feinberg School of Medicine, Northwestern University, Chicago, USA ConferenceASCO GU 2021 24 March, 2021 14:49
Apalutamide prolongs progression-free survival in prostate cancer Presented ByDr Dana Rathkopf, Memorial Sloan Kettering Cancer Center, New York, USA TrialPhase 3, ACIS ConferenceASCO GU 2021 24 March, 2021 14:49
Dose-intensified radiation therapy fails to provide better outcomes in prostate cancer Presented ByProf. Pirus Ghadjar, Charité Universitätsmedizin Berlin, Germany TrialPhase 3, SAKK 09/10 ConferenceASCO GU 2021 24 March, 2021 14:48
Intrinsic tumour biology may be predictive of treatment response in prostate cancer Presented ByProf. Felix Feng, University of California San Francisco, USA TrialPhase 3, SPARTAN ConferenceASCO GU 2021 24 March, 2021 14:46
Final TITAN trial results favour use of apalutamide Presented ByDr Kim Chi, British Columbia Cancer and Vancouver Prostate Centre, Canada TrialPhase 3, TITAN ConferenceASCO GU 2021 24 March, 2021 14:46
Ultra-high single-dose radiotherapy promising in some with prostate cancer JournalJAMA Oncology 17 March, 2021 17:21
Roche joins AstraZeneca in ditching U.S. bladder cancer indication for immunotherapies 8 March, 2021 16:55
Organ-sparing penile cancer surgery tied to better patient-reported outcomes JournalUrology 3 March, 2021 23:06
Prostate CA bone lesions, locations can predict survival benefits of add-on radiation JournalJAMA Oncology 26 February, 2021 23:34
Prostate CA bone lesions, locations can predict survival benefits of add-on radiation JournalJAMA Oncology 26 February, 2021 23:34
MRI-based test promising for mass prostate-cancer screening JournalJAMA Oncology 24 February, 2021 14:58
Photoselective vaporization safely alleviates refractory LUTS in prostate cancer patients JournalUrology 23 February, 2021 23:35
No benefit of dose-intensified salvage radiation for prostate-cancer recurrence ConferenceASCO 2021 Genitourinary Cancers Symposium 22 February, 2021 17:28
Adjuvant nivolumab prolongs disease-free survival in high-risk urothelial carcinoma ConferenceASCO 2021 Genitourinary Cancers Symposium 19 February, 2021 20:59
Apalutamide added to ADT prolongs life in men with metastatic castration-sensitive prostate cancer ConferenceASCO 2021 Genitourinary Cancers Symposium 19 February, 2021 20:54
22-gene classifier may help guide decision making after radical prostatectomy JournalJAMA Oncology 19 February, 2021 19:13
Transient drop in erectile function seen after prostate biopsy JournalUrology 18 February, 2021 16:49
Abundance of plasma cells tied to better outcomes in Blacks with prostate cancer JournalNature Communications 16 February, 2021 22:14
Uptick in diagnoses of metastatic prostate cancer tied to reduced PSA screening ConferenceASCO 2021 Genitourinary Cancers Symposium 12 February, 2021 16:47
MRI-targeted biopsy may be of added value in prostate-cancer detection JournalJAMA Oncology 10 February, 2021 16:39
Liquid biopsies helpful in prostate cancer, but most not ready for routine use JournalEuropean Urology 29 January, 2021 23:58
Post-prostatectomy urinary outcomes vary widely by patient and surgeon JournalJAMA Surgery 27 January, 2021 23:27
Aspirin tied to improved breast, bladder cancer survival in older adults JournalJAMA Network Open 26 January, 2021 21:33
Statin use tied to better outcomes in men with prostate cancer starting androgen-deprivation therapy JournalEuropean Urology 7 January, 2021 19:00
Two cases show fetus can get lung cancer during delivery if mother has cervical cancer JournalThe New England Journal of Medicine 6 January, 2021 23:00
Pembrolizumab plus bevacizumab and oral cyclophosphamide beneficial in recurrent ovarian cancer JournalJAMA Oncology 2 December, 2020 22:45
Androgen-deprivation therapy linked to worse fitness, CV mortality JournalJACC: CardioOncology 1 December, 2020 21:32
First-line immune-combination therapies in mUC TrialPhase 3, KEYNOTE-361 ConferenceESMO 2020 25 November, 2020 14:43
Liquid-biopsy testing in prostate cancer may lead to inappropriate treatment JournalJAMA Oncology 11 November, 2020 18:01
Platinum-based therapy could be helpful in some with advanced prostate cancer JournalJAMA Network Open 5 November, 2020 18:03
Active surveillance appears to be safe option for Black men with low-risk prostate cancer JournalJAMA 3 November, 2020 18:53
New prostate-cancer staging system may improve pretreatment prognostication JournalJAMA Oncology 30 October, 2020 19:18
Image-guided intensity-modulated radiation cuts late GI toxicity after cervical cancer ConferenceASTRO 2020 30 October, 2020 19:15
Men with localized prostate cancer have reduced long-term quality of life JournalBMJ 29 October, 2020 19:26
Women with cervical cancer at increased risk of injury during diagnostic workup JournalCancer Epidemiology, Biomarkers & Prevention 21 October, 2020 22:18
Rates of bone density testing in men initiating ADT low but rising JournalJournal of the National Comprehensive Cancer Network 21 October, 2020 16:08
Upfront chemo does not appear to worsen ovarian-cancer survival JournalJAMA Network Open 12 October, 2020 20:17
Radiation therapy, brachytherapy outcomes similar for localized prostate cancer JournalJAMA Network Open 7 October, 2020 22:40
Quality of life appears to suffer little when adding radiation to androgen deprivation for prostate cancer JournalEuropean Urology 6 October, 2020 18:44
Delaying radiation likely preferable after localized prostate cancer resection JournalThe Lancet 5 October, 2020 23:11
HPV vaccination tied to lower risk of invasive cervical cancer JournalNew England Journal of Medicine 30 September, 2020 23:00
Proton-pump inhibitors may reduce benefits of atezolizumab in urothelial carcinoma JournalClinical Cancer Research 23 September, 2020 18:12
Avelumab shows survival benefit against advanced urothelial cancer JournalNew England Journal of Medicine ConferenceESMO 2020 21 September, 2020 23:27
Urothelial cancer: avelumab works as maintenance therapy ExpertProf. Thomas Powles, Barts Cancer Institute, UK TrialPhase 3, JAVELIN Bladder 100 ConferenceASCO 2020 17 September, 2020 14:30
ARAMIS final OS and nmCRPC safety outcomes ExpertProf. Karim Fizazi, Institut Gustave Roussy, France TrialPhase 3, ARAMIS ConferenceASCO 2020 17 September, 2020 14:11
Final survival results from phase 3 SPARTAN trial ExpertProf. Eric J. Small, University of California San Francisco, CA, USA TrialPhase 3, SPARTAN ConferenceASCO 2020 17 September, 2020 14:01
Novel drug for kidney cancers/VHL patients ExpertProf. Eric Jonasch, University of Texas MD Anderson Cancer Center, USA TrialPhase 2 ConferenceASCO 2020 17 September, 2020 13:59
Primary analysis from IMvigor010, adjuvant atezolizumab in high risk muscle-invasive urothelial carcinoma ExpertDr Maya H.A. Hussain, Northwestern University in Chicago, IL, USA TrialPhase 3, IMvigor010 ConferenceASCO 2020 17 September, 2020 13:57
First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel ExpertProf. Michael S. Hofman, Peter MacCallum Cancer Centre, Australia TrialTheraP ConferenceASCO 2020 17 September, 2020 13:54
Follow-up confirms apalutamide survival benefits in some men with prostate cancer JournalEuropean Urology 16 September, 2020 20:56
Androgen deprivation appears beneficial in unfavorable intermediate-risk PC JournalJAMA Network Open 11 September, 2020 19:23
Accurate prediction of bladder-cancer response to neoadjuvant chemotherapy remains elusive JournalEuropean Urology 10 September, 2020 16:04
Darolutamide lowers risk of death by 31% for some prostate-cancer patients JournalNew England Journal of Medicine 9 September, 2020 23:00
Ipilimumab prolongs overall survival in metastatic castration-resistant prostate cancer JournalEuropean Urology 8 September, 2020 15:40
Maintenance olaparib improves OS in relapsed ovarian cancer with BRCA1/2 mutation Presented ByProf. Andrés Poveda, Hospital Quironsalud, Spain TrialPhase 3, SOLO2/ENGOT-ov21 ConferenceASCO 2020 8 September, 2020 09:35
DNA-methylation test shows promise in bladder-cancer detection, monitoring JournalJournal of Clinical Investigation 7 September, 2020 17:57
Infertility and testis cancer risk: causal or association? Presented ByProf. Leendert Looijenga , Princess Máxima Center for Pediatric Oncology, the Netherlands ConferenceEAU 2020 24 August, 2020 14:15
Prostatectomy: R-LRPE better than LRPE for continence Principal InvestigatorProf. Jens-Uwe Stolzenburg , University of Leipzig, Germany TrialLAP-01 ConferenceEAU 2020 21 August, 2020 14:49
PSMA PET-CT staging is 27% more accurate Principal InvestigatorProf. Michael Hofman, Peter MacCallum Cancer Centre, Australia TrialProPSMA ConferenceEAU 2020 21 August, 2020 14:40
Docetaxel + hormonal therapy: improved prostate cancer PFS Presented ByDr Andreas Josefsson , Sahlgrenska University Hospital, Sweden TrialPhase 3, SPCG-14 ConferenceEAU 2020 21 August, 2020 14:34
ARAMIS subgroup analysis: darolutamide benefits across PSADT groups Principal InvestigatorProf. Martin Bögemann, University of Münster, Germany TrialPhase 3, ARAMIS ConferenceEAU 2020 21 August, 2020 13:42
Large patient-driven survey reveals QoL issues after prostate cancer treatment Presented ByMr André Deschamps , Europa Uomo, Belgium TrialEUPROMS ConferenceEAU 2020 20 August, 2020 13:05
Targeting steroid sulphatase in resistant prostate cancer cells Presented ByProf. Allen C. Gao , University of California Davis, USA ConferenceEAU 2020 20 August, 2020 13:00
Good tolerance of post-RP radiotherapy ± short-term ADT Presented ByDr Paul Sargos , Institut Bergonié, France TrialPhase 2, GETUG-AFU 22 ConferenceEAU 2020 20 August, 2020 12:54
Reduced BCG frequency, faster NMIBC recurrence Presented ByProf. Marc-Oliver Grimm, University Hospital Jena, Germany TrialPhase 3, NIMBUS ConferenceEAU 2020 20 August, 2020 12:51
Nadofaragene firadenovec effective in BCG-unresponsive papillary NMIBC Presented ByDr Neal Shore, Carolina Urologic Research Center, USA ConferenceEAU 2020 20 August, 2020 12:44
Understanding MIBC biology for novel treatment options Presented ByProf. Yohann Loriot, Université Paris-Saclay, France TrialBLC2001; THOR; EV-301; EV-302; TROPHY-U-01; RANGE ConferenceEAU 2020 20 August, 2020 12:36
Ovarian cancer patients benefit from combined maintenance therapy Presented ByProf. Isabelle Ray-Coquard, Université Claude Bernard, Lyon, France TrialPhase 3, PAOLA-1/ENGOT-ov25 ConferenceESMO 2019 26 November, 2019 23:25
25% reduction in the risk of death in patients with nmCRPC treated with apalutamide Presented ByProf. Matthew Smith, Massachusetts General Hospital, Boston, USA TrialPhase 3, SPARTAN ConferenceESMO 2019 26 November, 2019 23:23
Combination of PARP inhibition plus chemotherapy in ovarian cancer Presented ByRobert Coleman, University of Texas, MD Anderson Cancer Center, Houston, USA TrialPhase 3, VELIA ConferenceESMO 2019 26 November, 2019 22:26
Enfortumab vedotin and pembrolizumab in advanced bladder cancer: initial results Presented ByProf. Christopher Hoimes, Case Comprehensive Cancer Center, Cleveland, USA TrialPhase 1, EV-103 ConferenceESMO 2019 26 November, 2019 22:23
PARP inhibition in selected patients slows progression on advanced prostate cancer Presented ByProf. Maha Hussain, Northwestern University, Chicago, USA TrialPhase 3, PROfound ConferenceESMO 2019 26 November, 2019 21:24
PFS extension with immunotherapy + chemotherapy in urothelial cancer Presented ByDr Enrique Grande, MD Anderson Cancer Centre Madrid, Spain TrialIMvigor130 ConferenceESMO 2019 26 November, 2019 21:24
Third-line in mCRPC: CARD trial Presented ByProf. Ronald De Wit, Erasmus University Rotterdam, the Netherlands TrialCARD ConferenceESMO 2019 26 November, 2019 20:24
Prostate cancer: spare radiotherapy after surgery Presented ByProf. Chris Parker, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UK TrialRADICALS-RT ConferenceESMO 2019 26 November, 2019 18:24
PFS benefit with niraparib as first-line maintenance in ovarian cancer Principal InvestigatorProf. Antonio González Martín, Clinica Universidad de Navarra, Spain TrialPhase 3, PRIMA/ENGOT-OV26/GOG-3012 ConferenceESMO 2019 26 November, 2019 14:26
Enzalutamide offers survival advantage over other NSAAs in mHSPC Presented ByDr Christopher Sweeney, Dana-Farber Cancer Institute, USA TrialENZAMET, TITAN ConferenceASCO 2019 15 July, 2019 23:26
Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer Presented ByDr Kim N. Chi, BC Cancer Agency, Canada TrialPhase 3, TITAN ConferenceASCO 2019 15 July, 2019 22:28
Enfortumab vedotin highly active in previously treated advanced urothelial carcinoma Presented ByDr Daniel P. Petrylak, Yale School of Medicine, USA TrialEV-201, EV-301 ConferenceASCO 2019 15 July, 2019 13:42
Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer Presented ByProf. Antonio Alcaraz, Prof. Noel Clarke TrialPhase 3, ARCHES ConferenceEAU 2019 21 May, 2019 23:59
Largest safety study of its kind with atezolizumab in metastatic bladder cancer Presented ByProf. Axel Merseburger, Prof. Jens Bedke TrialPhase 3, SAUL, IMvigor211 ConferenceEAU 2019 21 May, 2019 23:38
HPV and penile cancer Presented ByDr Andrea Salonia, Prof. Stéphane Droupy, Dr Philippe Spiess ConferenceEAU 2019 21 May, 2019 23:20
Prostate cancer active surveillance: Better patient risk stratification and use of imaging Presented ByDr Todd Morgan, Dr Vasilis Stavrinides, Dr Marco Bandini ConferenceEAU 2019 21 May, 2019 22:03
Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer Presented ByProf. Jürgen Gschwend, Prof. Sergio Bracarda ConferenceEAU 2019 21 May, 2019 21:47
The role of pelvic lymph node dissection in prostate cancer: Extended vs standard Presented ByDr Karim Touijer, Dr Akshay Sood ConferenceEAU 2019 21 May, 2019 21:10
When to use imaging and imaging-guided therapies Presented ByDr Lorenzo Bianchi, Dr Carlo Andrea Bravi ConferenceEAU 2019 21 May, 2019 20:53
FGFR3 gene mutation: Favourable prognostic impact in bladder cancer Presented ByDr Laura Mertens, VU Amsterdam Medical Center, the Netherlands ConferenceEAU 2019 21 May, 2019 20:52
Bladder cancer in young patients Presented ByDr Roland Seiler, Prof. Morgan Rouprêt, Prof. Fiona Burkhard TrialIMvigor 210 ConferenceEAU 2019 21 May, 2019 19:55
Radioguided surgery is the future? Presented ByDr Sophie Knipper, University Hospital Hamburg-Eppendorf, Germany ConferenceEAU 2019 21 May, 2019 19:54
Spanish study directly links surgical volume with mortality in bladder cancer patients undergoing cystectomy Presented ByDr Ana Guijarro Cascales, Hospital Universitario Fundacion Alcorcon, Spain ConferenceEAU 2019 21 May, 2019 18:57
Cytoreductive radical prostatectomy: LoMP trial results TrialLoMP ConferenceEAU 2019 21 May, 2019 18:24
Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG Presented ByProf. Ashish Kamat, MD Anderson Cancer Center, Houston, USA TrialKEYNOTE-057, KEYNOTE-676 ConferenceEAU 2019 21 May, 2019 17:01
Prostate cancer: What to expect the next 12 months TrialSTAMPEDE, ENZAMET ConferenceEAU 2019 21 May, 2019 10:27
Robot-assisted radical cystectomy or open radical cystectomy? Presented ByProf. Jens Bedke, Prof. Seth Lerner, Prof. James Catto TrialRAZOR, iROC ConferenceEAU 2019 21 May, 2019 09:05